In a recent announcement, Dr. Seth Lederman, CEO of Tonix Pharmaceuticals, appeared on Proactive with Steve Darling to reveal that their COVID-19 vaccine, TNX-1800, has been selected for testing in Project Next Gen. This initiative is managed by the White House and the Department of Health and Human Services, NIH, and NIAID.
TNX-1800 uses a live virus platform that provides a unique way of stimulating the immune system. This method offers longer-lasting and potentially transmission-blocking immunity compared to mRNA vaccines. The selection of TNX-1800 for this program highlights Tonix Pharmaceuticals’ almost ten years of dedication to vaccine development. Furthermore, the technology platform can be adapted to protect against other infectious diseases such as monkeypox, smallpox, and tuberculosis.
The choice of TNX-1800 represents the importance of vaccine platforms in addressing various infectious threats. Tonix’s approach offers the promise of more durable immunity and potential transmission prevention, potentially revolutionizing our approach to infectious disease control. The platform’s adaptability makes it a valuable tool for future vaccine strategies, making it a versatile solution for future pandemics.
For more information about TNX-1800 and Project Next Gen, please contact Proactive Studio at +1 347-449-0879 or email them at na-editorial@proactiveinvestors.com